Screening for testicular cancer is ineffective

In adolescent and young adult males, palpation of the testicles for signs of cancer has traditionally been part of the preparticipation sports physical or well-child examination. Unlike most malignancies that predominantly affect older adults, testicular cancer is most commonly diagnosed between 15 and 34 years of age. Nonetheless, screening for testicular cancer has long been something I have discouraged my students and residents from doing. The rationale is twofold: it's rare, so screening will lead to many false positives and unnecessary evaluations; and more importantly, it's curable even at advanced stages, so earlier detection provides little to no incremental benefit. These were the reasons why in 2011, the U.S. Preventive Services Task Force (USPSTF) reaffirmed its previous recommendation against testicular cancer screening, based on an evidence review that I co-authored that found no new evidence to change this conclusion.

Others have dissented over the years. They argue that young men are among the least likely to visit a doctor and most likely to ignore early symptoms of testicular cancer. American cyclist Lance Armstrong was famously diagnosed with stage 3 testicular cancer at age 24 after ignoring the warning signs for months, having become used to intermittent groin pain and fatigue from grueling hundred-mile training rides up the sides of mountains. (After surgery and chemotherapy, Armstrong not only survived, but went on to win the Tour de France a record seven consecutive times before having his titles rescinded for doping.)

The most salient argument against the USPSTF's "D" recommendation is that until recently, no one had actually studied the outcomes of a sizable real-world program of testicular cancer screening. Consequently, this critique stated, the recommendation grade should be "I" (insufficient evidence). In fact, I have been concerned that the Task Force's 2018 reversal on prostate cancer screening (from "D" to "C" in men age 55 to 69 years) foreshadowed a similar change of heart on testicular cancer the next time they decided to revisit the topic.

A recently published paper appears to have closed the door on that possibility. A team of researchers performed a retrospective cohort study of more than 300,000 Israeli males age 16 to 21 years who had testicular examinations between 2012 and 2021 as part of medical screening evaluations for mandatory military service. All participants were followed for the duration of their service (generally 3 years). 43 testicular cancers developed during the study (incidence rate of 3.67 per 100,000 person-years); even though the vast majority were diagnosed clinically rather than through screening, 86% were stage 1. Of the 6 cancers determined to have been present at the initial exam (diagnosed within 6 months), screening detected 4 at the cost of 804 false positives. More than 75,000 screening exams, 176 ultrasound scans, and 112 urologist visits were required to detect a single cancer. The researchers concluded that "the low sensitivity, high number needed to screen, frequent unnecessary evaluations, and low incidence of testicular cancer suggest that routine screening of asymptomatic adolescents is ineffective."

source http://commonsensemd.blogspot.com/2026/05/screening-for-testicular-cancer-is.html